Depleting blood NAR through nutritional or genetic manipulations was synthetically lethal to tumors when combined with NAMPT inhibitors, suggesting a rationale for simultaneously targeting NAR metabolism and NAMPT as a therapeutic strategy in neuroendocrine carcinoma [134]. The gene discussed is NAMPT; the disease is neuroendocrine carcinoma.